阿瑪琳 AMRN 深 滬
已收盤 02-06 16:00:00 美东时间
14.75
+0.660
+4.68%
華盛通- 最 高14.99
- 今 開14.32
- 成交量 8.94万股
- 最 低 14.14
- 昨 收 14.09
- 總市值 3.07亿
- 52周最高 20.90
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 7.08
- 委 比 94.17%
- 總股本 2079.27万
- 歷史最高 522.40
- 量 比 1.19
- 振 幅 6.03%
- 歷史最低 7.08
- 每 手 1
- 風險率 2.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amarin Reports $217M Revenue and $303M Cash in Preliminary Full-Year 2025 Results
Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary unaudited 2025 financial highlights, provided a summary of key 2025
01-08 20:14
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
Amarin Corporation plc reported strong financial performance in 2025, achieving positive cash flow in Q4 and ending the year with a cash balance of $303 million. They sustained market leadership in the U.S. for VASCEPA, with over 50% of IPE prescriptions, and expanded their presence in Europe through a partnership with Recordati, commercializing VAZKEPA in 59 countries. The company also secured regulatory approvals in South Korea and Singapore. W...
01-08 12:00
Amarin To Present New Data Highlighting VASCEPA's Cardiovascular Benefits And EPA's Anti-Inflammatory, Antioxidant Mechanisms At AHA 2025
Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana.
2025-11-03 21:41
Amarin shares are trading lower. The company reported Q3 financial results.
Amarin shares are trading lower. The company reported Q3 financial results.
2025-10-30 02:22
Amarin Corp Q3 2025 Adj per ADS $0.19 Up From $(1.00) YoY, Sales $49.670M Beat $43.099M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.19 per share. This is a 119 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $49.670
2025-10-29 19:17
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
Amneal Pharmaceuticals launched Brekiya® autoinjector, the first and only ready-to-use dihydroergotamine (DHE) autoinjector for treating migraines and cluster headaches in adults. Available exclusively through Walgreens and Sterling Specialty Pharmacies, Brekiya offers patients a convenient alternative to emergency room visits. Migraines affect 43 million Americans, and cluster headaches impact 300,000 individuals, with limited treatment options ...
2025-10-27 12:00
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
Amarin Corporation plc applauds the FDA's decision to update fenofibrate labeling, emphasizing no cardiovascular benefits and increased risks when combined with statins. Clinical trials like FIELD, ACCORD Lipid, and PROMINENT show fenofibrates don't reduce cardiovascular events. Despite this, fenofibrates remain widely prescribed, with over 11 million U.S. prescriptions in 2023. Amarin倡导使用科学证据支持的疗法，如其产品VASCEPA，以帮助患者减少心血管事件风险。公司CEO Aaron Berg赞扬了FD...
2025-10-27 12:00
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
Amarin Corporation plc announced it will report third quarter 2025 financial results and host a conference call on October 29, 2025. The press release will be issued pre-market, followed by the call at 8:00 a.m. ET. Participation details include telephone access via 877-545-0523 (US) or 973-528-0016 (international) with code 459510, and online via a webcast on www.amarincorp.com. A replay will be available through the same channels shortly after ...
2025-10-15 12:00
HLS Therapeutics And Amarin To Present IPE And EPA Mechanistic Effects At Canadian Cardiovascular Congress 2025
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, in collaboration with its
2025-10-14 20:48
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Amarin Corporation plc and HLS Therapeutics are presenting scientific data on Icosapent Ethyl (IPE) and Eicosapentaenoic Acid (EPA) at the 2025 Canadian Cardiovascular Congress. The research highlights the clinical value of IPE for cardiometabolic conditions and explores EPA's effects on atherogenic lipoproteins and endothelial cells during inflammation when combined with a GLP-1 receptor agonist. Featured abstracts include studies on IPE's reduc...
2025-10-14 12:00
